← back to search

Aldo M. Roccaro

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · IT
Area of research
Hematology · Genetics
Research interest
Research interests include Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors, and Chemokine receptors and signaling.
h-index
63
citations
12,728
works
521
NIH funding
primary concept
Medicine
email

Recent publications

Report of Consensus Panel 4 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma
Seminars in Hematology 2025cited by 4position: middledoi
ClpP: a new Achilles' heel in myeloma.
2025cited by 0position: contributordoi
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
2024cited by 7position: contributordoi
Waking up exhausted BCMA-specific T cells in myeloma.
2024cited by 1position: contributordoi
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia.
2023cited by 31position: contributordoi
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.
2023cited by 27position: contributordoi
Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis.
2023cited by 11position: contributordoi
Starving multiple myeloma cells via CDK7 inhibition.
2023cited by 0position: contributordoi
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Data from FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation–Induced Mitochondrial Oxidative Stress
2023cited by 0position: contributordoi
Supplementary Figures 1-15, Supplementary Table 1 from ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment
2023cited by 0position: contributordoi
Supplementary Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Data from FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation–Induced Mitochondrial Oxidative Stress
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Methods from ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment
2023cited by 0position: contributordoi
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi
Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 25 papers (2019–2025)Antonio Sacco · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia20 papers (2012–2025) · 9 papers (2021–2023)Niccolò Bolli · Creative Commons8 papers (2021–2023)Irene M. Ghobrial · Harvard University8 papers (2012–2020)Yu-Tzu Tai · Cancer Research Center7 papers (2021–2023)Anil Aktas-Samur · Cancer Research And Biostatistics7 papers (2021–2023)Marco Presta · University of Brescia7 papers (2020–2023)Matteo Claudio Da Vià · Universitätsklinikum Würzburg7 papers (2021–2023)Tianzeng Chen · Chinese Academy of Sciences7 papers (2021–2023)Giada Bianchi · University of Pennsylvania7 papers (2021–2023)Tomasz Sewastianik · Harvard University7 papers (2021–2023)Marco Mor · United States Food and Drug Administration6 papers (2020–2023)Salomon Manier · CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers6 papers (2012–2020)Carmelo Carlo‐Stella · Humanitas University6 papers (2020–2023)Riccardo Castelli · Eidgenossische Technische Hochschule Zurich Laboratorium fur Organische Chemie5 papers (2020–2023)Sara Taranto · University of Brescia5 papers (2020–2023) · 5 papers (2020–2023) · 4 papers (2023–2025)Michele Moschetta · University of Lausanne4 papers (2014–2020)